Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of 1 of the following:

- Invasive carcinoma of the cervix meeting all of the following criteria:

- Previously untreated, primary disease

- Locoregionally advanced (stage IB2, IIA [≥ 4 cm], or IIB-IVA) disease

- Any cell type allowed

- High-risk endometrial carcinoma meeting 1 of the following criteria:

- Grade 3 endometrioid or non-endometrioid endometrial carcinoma (clear cell
or serous papillary) or carcinosarcoma diagnosed from an endometrial biopsy
or dilation and curettage

- Grade 1 or 2 endometrioid endometrial carcinoma with cervical stromal
involvement overt on clinical examination or confirmed by endocervical
curettage

- Under consideration for chemoradiotherapy (patients with cervical cancer)

- Undergone appropriate surgery for cervical or endometrial carcinoma with appropriate
tissue available for histologic evaluation to confirm diagnosis and stage

- Appropriate surgical candidate to undergo extraperitoneal or laparoscopic lymph node
sampling OR hysterectomy and lymph node sampling

- No surgery for patients with advanced lymphadenopathy

- No recurrent invasive carcinoma of the uterus or uterine cervix regardless of
previous treatment

- No known metastases to the lungs or scalene lymph nodes

- No metastases to other organs outside of the pelvis or abdominal lymph nodes at the
time of the original clinical diagnosis

- Patients with endometrial cancer with known intraperitoneal disease are eligible
provided they undergo pelvic and para-aortic lymphadenectomy per protocol

- Participants must be enrolled at an ACRIN-affiliated institution that is accredited
by GOG

- GOG performance status 0-2

- Creatinine within normal institutional limits OR, in participants with creatinine
levels above institutional normal, glomerular filtration rate (GFR) must be > 60
mL/min; there is no lower limit of normal for serum creatinine for this protocol

- Ferritin levels ≤ 600 ng/mL OR saturation of transferrin level ≤ 50%

- Patients with high levels of ferritin or transferrin are eligible if documented
hematology rules out iron overload

- Not pregnant or nursing

- Negative pregnancy test

- No patients weighing greater than that allowable by the PET/CT scanner

- No renal abnormalities, such as a pelvic kidney, horseshoe kidney, or renal
transplantation, that would require modification of the lymphadenectomy

- No history of anaphylactic or life-threatening allergic reactions to any contrast
media

- No other invasive malignancies within the past 5 years with the exception of
nonmelanoma skin cancer

- No contraindication to MRI (e.g., severe claustrophobia, pacemaker, aneurysm clips,
defibrillators, or other institutional contraindication to MRI)

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to ferumoxtran-10 (e.g., iron preparations, parenteral iron,
parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide
preparations)

- No immunodeficiencies that would predispose patient to specific or nonspecific
mediator release

- No history of cirrhosis

- No poorly controlled, insulin-dependent diabetes (i.e., fasting blood glucose level >
200 mg/dL)

- No prior pelvic or abdominal lymphadenectomy

- No prior pelvic radiotherapy

- No prior anticancer therapy that would contraindicate study participation

- No ferumoxides within the past 2 weeks

- No investigational agents within the past 30 days

- No other concurrent investigational agents